There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...
GlobalData on MSN4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
ThePrint on MSN3d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavirGranting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback